Pharma's Almanac

Priority Review

Mobile Navigation

Subscribe for the Newsletter

Priority Review

Priority Review

Novartis Lung Cancer Drug Granted Priority FDA Review

Novartis

M&A

AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi

Nice Insight

Priority Review

Melinta’s Antibiotic Baxdela Gets Priority Review from FDA for CAPB

Pharma's Almanac

NDA

U.S. FDA Grants Priority Review For Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication

Amarin

FDA Acceptance

Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD

Novartis

Priority Review

FDA Grants Priority Review to Dupixent for Treatment of Adults with Severe Chronic Rhinosinusitis

Emilie Branch

Pharma's Almanac

FDA

FDA Gives Novartis Gene Replacement Therapy Application Priority Review

Emilie Branch

Pharma's Almanac

Drug Application

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

Bayer

CFDA

China FDA Publishes Guidance for Priority Review

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Priority Review

Novartis Lung Cancer Drug Granted Priority FDA Review

Novartis

M&A

AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi

Nice Insight

Priority Review

Melinta’s Antibiotic Baxdela Gets Priority Review from FDA for CAPB

Pharma's Almanac

NDA

U.S. FDA Grants Priority Review For Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication

Amarin

FDA Acceptance

Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD

Novartis

Priority Review

FDA Grants Priority Review to Dupixent for Treatment of Adults with Severe Chronic Rhinosinusitis

Emilie Branch

Pharma's Almanac

FDA

FDA Gives Novartis Gene Replacement Therapy Application Priority Review

Emilie Branch

Pharma's Almanac

Drug Application

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

Bayer

CFDA

China FDA Publishes Guidance for Priority Review

Cynthia A. Challener, Ph.D.

Pharma's Almanac